Loading…

Activated leukocyte cell adhesion molecule soluble form: a potential biomarker of epithelial ovarian cancer is increased in type II tumors

Activated leukocyte cell adhesion molecule (ALCAM) is involved in cell–cell interactions in cancer. Shedding of its ectodomain by the metalloprotease ADAM17/TACE generates a soluble form (sALCAM). Here, we show that serum sALCAM levels were significantly higher in epithelial ovarian cancer (EOC) (p...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cancer 2013-06, Vol.132 (11), p.2597-2605
Main Authors: Carbotti, Grazia, Orengo, Anna Maria, Mezzanzanica, Delia, Bagnoli, Marina, Brizzolara, Antonella, Emionite, Laura, Puppo, Andrea, Centurioni, Maria Grazia, Bruzzone, Milena, Marroni, Paola, Rossello, Armando, Canevari, Silvana, Ferrini, Silvano, Fabbi, Marina
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Activated leukocyte cell adhesion molecule (ALCAM) is involved in cell–cell interactions in cancer. Shedding of its ectodomain by the metalloprotease ADAM17/TACE generates a soluble form (sALCAM). Here, we show that serum sALCAM levels were significantly higher in epithelial ovarian cancer (EOC) (p < 0.005) than in controls. The performance of sALCAM as classifier, tested by receiver operating characteristic curve, resulted in an area under the curve (AUC) of 0.8067. Serum sALCAM levels showed direct correlation with Carbohydrate Antigen‐125 (CA125/MUC16). Moreover, significantly higher levels were found in type II tumors, even in stage I/II, suggesting that elevated sALCAM is an early feature of aggressive EOC. In addition, sALCAM levels were higher in ascites than in sera, suggesting local processing of ALCAM in the peritoneal cavity. In immunodeficient mice, intraperitoneally implanted with a human EOC cell line, human sALCAM progressively increased in serum and was even higher in the ascites. The biochemical characterization of the sALCAM in EOC sera and ascites, showed two predominant forms of approximately 95 and 65 kDa but no EOC‐specific isoform. In addition, full‐length transmembrane ALCAM but no soluble form was detected in tumor‐derived exosomes found in ascites. Finally, in vitro invasion assays showed that inhibition of ADAM17/TACE activity decreased EOC invasive properties, while opposite effects were mediated by a sALCAM‐Fc chimera and by an antibody interfering with ALCAM/ALCAM interactions. Altogether these data suggest that sALCAM is a marker of EOC, which correlates with more aggressive type II tumors, and that ADAM17/TACE activity and sALCAM itself mediate enhanced invasiveness. What's new? The intercellular adhesion protein activated leukocyte cell adhesion molecule (ALCAM), or CD166, has been variously associated with cancer progression. Its soluble form, sALCAM, which is formed by ADAM17/TACE metalloprotease activity, could be an important biomarker for certain types of cancer. In this investigation of epithelial ovarian cancer, increased serum levels of sALCAM were correlated with CA125 level and more aggressive (type II) tumors. Both ADAM17/TACE activity and sALCAM were found to influence tumor invasiveness in vitro. The data support a role for ADAM17/TACE in ovarian cancer and indicate that sALCAM could serve as a marker for its activity.
ISSN:0020-7136
1097-0215
DOI:10.1002/ijc.27948